Import from '@/components/mdx'

Can I Take Vitamin B12 with Farxiga (Dapagliflozin)?

The Short Answer: No Direct Interaction, But Context Matters

Vitamin B12 and Farxiga do not interfere with each other at the pharmacokinetic level. Dapagliflozin works by blocking the SGLT2 transporter in the kidney to increase urinary glucose excretion. Vitamin B12 is absorbed in the terminal ileum via intrinsic factor and transported through the bloodstream independently. These two pathways do not cross.

The question "can I take vitamin B12 with Farxiga" is worth asking, though, because it points to a real clinical pattern. Many women prescribed Farxiga are also on metformin, and metformin reduces B12 absorption by up to 30% through competitive inhibition of calcium-dependent ileal membrane receptors. Recognizing which drug is causing the problem matters for your care.

Why Women Ask This Question

Women are prescribed Farxiga for type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease (CKD). Women with polycystic ovary syndrome (PCOS) are also frequently on metformin for insulin resistance, and a clinician may add dapagliflozin as cardiometabolic risk rises with age. Separately, women across every life stage are common B12 supplement users, whether for energy, nerve health, or because they follow plant-based diets.

The overlap creates a reasonable concern. This article sorts out exactly what the evidence shows.

How Farxiga Works and Why It Does Not Deplete B12

Dapagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor. It blocks glucose reabsorption in the proximal tubule of the kidney, causing roughly 60 to 90 grams of glucose to be excreted in urine per day at the standard 10 mg dose. The result is lower blood glucose, modest weight loss, reduced blood pressure, and, through mechanisms including natriuresis and reduced cardiac preload, significant cardiovascular and renal protection.

Nothing in that mechanism touches B12 metabolism. Dapagliflozin does not alter gastric acid production, intrinsic factor secretion, or ileal transport. It does not bind to B12 or its carrier proteins. The FDA label for Farxiga lists no interaction with B12 or B-vitamin supplements.

What the DECLARE-TIMI 58 Trial Told Us About Women on Dapagliflozin

The DECLARE-TIMI 58 trial enrolled 17,160 patients with type 2 diabetes, roughly 37% of whom were women. It reported cardiovascular and renal outcomes but did not track B12 levels. The absence of B12-related signals in post-marketing surveillance supports the conclusion that dapagliflozin itself is not a B12 disruptor. Women-specific subgroup analyses from DECLARE-TIMI 58 showed similar cardiovascular benefit across sexes, with women experiencing slightly lower absolute event rates, which reflects their lower baseline cardiovascular risk in the trial population.

The DAPA-HF and DAPA-CKD Trials

DAPA-HF demonstrated a 26% reduction in worsening heart failure or cardiovascular death with dapagliflozin 10 mg versus placebo. DAPA-CKD showed a 39% reduction in a composite renal endpoint. Neither trial reported B12 interactions or deficiency as an adverse event.

The Real Risk: Metformin-Driven B12 Depletion in Women Who Take Both Drugs

This is where clinical attention is warranted. Many women with type 2 diabetes or PCOS are prescribed metformin first, then dapagliflozin is added for additional glycemic control or cardiorenal protection. In that combination, B12 depletion is a genuine concern, and it is driven entirely by metformin.

A large cross-sectional analysis published in Diabetes Care found that patients on metformin had significantly lower serum B12 levels compared to those not on metformin, with deficiency rates as high as 5.8% to 33% depending on the dose and duration. Duration of metformin use and higher doses both increase the risk.

Why Women With PCOS Face Compounded Risk

Women with PCOS are often started on metformin during their reproductive years, sometimes for a decade or more, for insulin resistance management. A woman who began metformin at age 25 for PCOS and is now 40, perimenopausal, and newly prescribed Farxiga for worsening metabolic health may have been silently depleting B12 for years. The American Diabetes Association recommends periodic B12 measurement for patients on long-term metformin, but this recommendation is not always enacted in practice.

B12 deficiency in this group can manifest as peripheral neuropathy, fatigue, mood changes, and macrocytic anemia. These symptoms overlap with hypothyroidism, perimenopause, and iron-deficiency anemia, all conditions more common in women, which means deficiency can be missed for years.

What Counts as B12 Deficiency and What to Do About It

Serum B12 below 200 pg/mL is generally considered deficient, and levels between 200 and 300 pg/mL are borderline and warrant further investigation with methylmalonic acid (MMA) and homocysteine, which are more sensitive functional markers. Elevated MMA in the setting of low-normal B12 confirms functional B12 deficiency even when serum B12 appears borderline.

For women on long-term metformin, oral cyanocobalamin at 1,000 mcg/day is sufficient to correct deficiency in most cases, because high-dose oral B12 can bypass the intrinsic-factor-dependent pathway through passive diffusion. Intramuscular injections are reserved for severe deficiency, malabsorption syndromes, or pernicious anemia.

Vitamin B12 Across Women's Life Stages

B12 needs and absorption change across a woman's life. Knowing your stage matters for understanding your personal risk.

Reproductive Years and Women Trying to Conceive

B12 is co-essential with folate for neural tube closure. Women trying to conceive should have adequate B12 status, and this is especially relevant for women who are vegan, vegetarian, or on long-term metformin for PCOS. The CDC recommends all women of reproductive age consume 400 mcg of folic acid daily, and adequate B12 supports folate metabolism. A woman on Farxiga who is trying to conceive needs a specific conversation about stopping dapagliflozin before or immediately after a positive pregnancy test (see pregnancy section below).

Perimenopause

Estrogen decline in perimenopause is associated with changes in gastric acid production and gastrointestinal motility, both of which can impair B12 absorption. Atrophic gastritis, which causes reduced intrinsic factor secretion, becomes more common after age 50 and affects up to 30% of older adults. A perimenopausal woman newly diagnosed with type 2 diabetes or heart failure and starting Farxiga should have baseline B12 checked if she is also on metformin, follows a plant-based diet, or has GI symptoms.

Post-Menopause

Post-menopausal women with type 2 diabetes, CKD, or heart failure are the most common recipients of Farxiga in clinical practice. They are also the group most likely to have subclinical B12 deficiency from dietary inadequacy or atrophic gastritis. Routine B12 screening in this population during medication review is good practice.

Postpartum

Women who used metformin during pregnancy (for gestational diabetes or type 2 diabetes) may have entered the postpartum period with B12 depletion. If Farxiga is being considered postpartum (after confirming non-breastfeeding status, discussed below), B12 levels should be checked before and after starting any combined metformin-dapagliflozin regimen.

Pregnancy and Lactation: What Every Woman Needs to Know

Farxiga is contraindicated in pregnancy, particularly from the second trimester onward. This is not a precautionary soft warning. Animal data show renal developmental toxicity at clinically relevant exposures, and the FDA label specifies that dapagliflozin should be discontinued when pregnancy is detected. The FDA prescribing information for Farxiga explicitly states that the drug can cause fetal harm and should be discontinued as soon as pregnancy is recognized.

What This Means for You at Each Stage

Trying to conceive: Women with type 2 diabetes, PCOS with metabolic complications, or CKD who are planning a pregnancy should discuss transitioning off Farxiga before conception, ideally working with their prescriber to switch to agents with established pregnancy safety such as insulin. The timing of discontinuation should be individualized.

First trimester: The risk period for renal dysgenesis from SGLT2 inhibitors is concentrated in the second and third trimesters based on animal data, but the safest approach is to stop dapagliflozin before or immediately upon confirmed pregnancy.

Lactation: Dapagliflozin is excreted in rat milk. Human lactation data are absent. Because of the potential for serious adverse effects on nursing infants, including renal toxicity, the FDA label advises against use during breastfeeding. Women who are breastfeeding and need pharmacologic glucose management should use insulin as the primary agent. ACOG supports insulin as the preferred agent for glycemic management during lactation.

Contraception: Women of reproductive age prescribed Farxiga need reliable contraception. This drug falls into the category of medications where an unplanned pregnancy carries meaningful drug-exposure risk. Discuss contraception method with your prescriber at the time Farxiga is started.

Vitamin B12 in pregnancy: If you are pregnant and were on metformin before conception, B12 status should be part of prenatal lab work. B12 deficiency during pregnancy is associated with increased risk of neural tube defects, preterm birth, and maternal fatigue. Oral or intramuscular B12 supplementation is safe throughout pregnancy.

Pharmacokinetic Profile of Dapagliflozin in Women

Sex-specific pharmacokinetic data for dapagliflozin show that women tend to have modestly higher area-under-the-curve (AUC) exposure compared to men at equivalent doses, likely reflecting differences in body composition and renal handling. The FDA clinical pharmacology review for Farxiga noted that sex was not a clinically significant covariate requiring dose adjustment, but women may experience slightly higher plasma concentrations.

This does not change B12 interaction risk. It does mean women may be somewhat more prone to volume-depletion effects, genital mycotic infections (which occur at higher rates in women on SGLT2 inhibitors due to glucosuria), and urinary tract infections. Genital mycotic infections were reported in up to 8.4% of women taking dapagliflozin in clinical trials versus roughly 1.5% in men. These are the side effects women need to watch for, not B12-related ones.

Should You Take Vitamin B12 If You Are on Farxiga Only (No Metformin)?

If you are taking dapagliflozin and not metformin, there is no drug-specific reason to supplement B12 beyond your usual dietary or personal health needs. Farxiga does not deplete B12 and does not impair its absorption.

Assess your individual baseline:

• Are you vegan or vegetarian? Dietary B12 intake may be insufficient regardless of what medications you take.
• Are you over 50? Absorption efficiency declines with age.
• Do you have symptoms of B12 deficiency: tingling in hands or feet, unexplained fatigue, cognitive fog, or mouth sores?
• Do you have CKD? Renal disease can affect multiple nutrient levels, and a comprehensive metabolic picture matters.

If any of those apply, ask your clinician for a serum B12 level. Supplementation at standard doses (1,000 mcg/day oral cyanocobalamin) carries no known risk and no interaction with Farxiga.

Who Is Most Likely to Benefit From B12 Testing When Taking Farxiga

The following women should have B12 measured at their next visit:

Women on metformin plus Farxiga: This is the primary group. The ADA recommends periodic monitoring, but "periodic" is loosely defined. A reasonable approach is baseline B12 at the time of adding Farxiga to a metformin regimen, then annually.

Women with PCOS on long-term metformin: As noted above, duration matters. Every year of metformin use accumulates depletion risk.

Perimenopausal or post-menopausal women with GI symptoms: Atrophic gastritis and reduced intrinsic factor production are common and often silent.

Women following plant-based diets: Dietary B12 comes almost exclusively from animal products. No plant food provides reliable B12 in meaningful amounts without fortification.

Women with peripheral neuropathy symptoms: Before attributing tingling or numbness to diabetic neuropathy, B12 deficiency should be ruled out. The two conditions can coexist and treating deficiency may improve symptoms that would otherwise be attributed solely to hyperglycemia-driven nerve damage.

Evidence Gaps: What We Do Not Yet Know

Women have been historically underrepresented in cardiometabolic trials. The DECLARE-TIMI 58 trial was approximately 37% female, and DAPA-HF enrolled roughly 23% women. Neither trial was powered to detect sex-specific differences in nutrient metabolism or B12 trajectories.

No dedicated study has examined B12 levels longitudinally in women on Farxiga without metformin. The conclusion that Farxiga does not deplete B12 is based on mechanism, not a large randomized trial. This is a reasonable inference given the drug's mode of action, and no signal has emerged in post-marketing data, but women should know it is a mechanistic inference rather than data from a 2,000-woman RCT with B12 endpoints.

The intersection of PCOS, metformin, Farxiga, and B12 in women across the reproductive lifespan is a research gap that no major trial has specifically addressed.

As WomanRx reviewer Maya Okafor, MD, notes: "The B12 question with Farxiga almost always turns out to be a metformin question in disguise. I check B12 on every patient I'm adding Farxiga to if they've been on metformin for more than a year, because deficiency at that point is common enough that I'd rather catch it than wait for symptoms."

Practical Checklist: Taking Vitamin B12 and Farxiga Together

Use this checklist as a starting point for your next clinical conversation, not a substitute for it.

1. Confirm which drugs you actually take. Is it Farxiga alone, or Farxiga plus metformin (or a combination tablet like Xigduo XR)? The answer changes your B12 risk profile entirely.
2. Ask for a serum B12 level if you are on metformin, over 50, vegan, or have neurological symptoms.
3. If B12 is low or borderline, ask your clinician about MMA and homocysteine testing to confirm functional deficiency.
4. Start oral cyanocobalamin 1,000 mcg/day if deficiency is confirmed, and recheck B12 in three to six months.
5. Do not stop Farxiga because of B12 concerns unless your clinician advises it. The cardiovascular and renal benefits are significant. Deficiency is manageable.
6. If you are pregnant or trying to conceive, speak with your prescriber about stopping Farxiga and transitioning to a pregnancy-safe alternative before or immediately upon confirmed pregnancy.
7. If you are breastfeeding, Farxiga should not be used. B12 supplementation is safe while breastfeeding and may be especially relevant if you were on metformin during pregnancy.